BOSTON, August 11, 2025 — Leads & Copy — Compass Therapeutics, Inc. (Nasdaq: CMPX) reported its second quarter 2025 financial results and provided a business update on its clinical and pre-clinical programs. The oncology-focused biopharmaceutical company is developing proprietary antibody-based therapeutics.
In a Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths were observed than projected, suggesting the drug may be affecting overall survival. Analysis of the secondary endpoints, including overall survival, is expected in Q1 2026.
In a Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses were observed. A patient with non-small cell lung cancer had a 100% reduction in target lesion tumor burden, and a patient with triple-negative breast cancer had >90% reduction. Cohort expansions are planned to begin in Q4 2025.
CTX-10726 (PD-1 x VEGF-A bispecific antibody) demonstrated superiority in both PD-1 inhibition and anti-tumor responses in mouse models compared to ivonescimab. IND filing is expected in Q4 2025, with clinical data in 2026.
Compass ended Q2 with $101 million in cash and marketable securities, expected to provide cash runway into 2027.
Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors.
Media Contact: Anna Gifford, Chief of Staff, media@compasstherapeutics.com, 617-500-8099
Investor Contact: ir@compasstherapeutics.com
Source: Compass Therapeutics, Inc.
